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Summary
Objective: To analyze the results of a postgraduate institute management protocol for invasive
Aspergillus flavus sinusitis.
Methods: This was a prospective study wherein all patients with a final histopathological
diagnosis of invasive sino-orbital aspergillosis were included for the period between January
1998 and December 2005. All the patients were negative for HIV, diabetes, and chronic
granulomatous disease. All patients were evaluated clinically, biochemically, and radiologically
for the condition, and were classified into four groups on the basis of clinical and radiological
findings. All patients were subjected to endonasal endoscopic biopsy and were subjected as per
the management protocol. These patients were then followed up clinically, endoscopically, and
radiologically for a period ranging from 9 months to 7 years.
Results: A total of 74 patients were enrolled in the study, 52 males and 22 females, ranging in age
from 26 to 53 years. The most common sign was proptosis. The patients in each group were
subjected to the treatment protocol decided for the group. Overall, residual disease was seen in
14 patients (18.9%) and recurrence was seen in six patients (8.1%). Twenty-four (32.4%) patients
died of the disease in our series. Residual disease and recurrent disease were seen more often in
the advanced cases.
Conclusion: Invasive sino-orbital aspergillosis is associated with significant mortality. By follow-
ing our management protocol we were able to reduce the mortality to 32.4% in our series.
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Invasive orbital aspergillosis in immunocompetent, healthy
individuals is an uncommon entity with fewer than 50* Corresponding author. Tel.: +91 172 2747585 94x6763;
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doi:10.1016/j.ijid.2008.03.035patients reported in the English literature so far. Most of
the reported patients with sino-orbital aspergillosis have had
the non-invasive allergic variant. The most common present-
ing symptom for the invasive variant is painless progressive
proptosis, and this variant is associated with a high degree of
morbidity and mortality. There is no consensus on the man-
agement protocol for this disease.1—5 We present herein our
experience of managing this entity at our institute followingational Society for Infectious Diseases.
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1998 to December 2005. This is, to-date, the single largest
study of immunocompetent individuals suffering from this
condition from a single center. The protocol was approved by
the local institute ethics committee.
Materials and methods
This was a prospective study conducted at the Department of
Otolaryngology and Head and Neck Surgery, Postgraduate
Institute of Medical Education and Research, Chandigarh,
India, wherein all patients with a histopathological diagnosis
of invasive sino-orbital aspergillosis or isolated orbital asper-
gillosis were enrolled. The patients with the allergic variant
of the condition were excluded on the basis of their clinical
profile with features of excessive sneezing, rhinorrhea,
raised IgE levels, Charcot—Leyden crystals, and allergic
mucin on histopathology. The major study exclusion/inclu-
sion criteria were based on histopathology, which in the
allergic variant shows allergic mucin, Charcot—Leyden crys-
tals, and no fungal hyphae within the soft tissues; the
invasive variant in the chronic form shows formation of giant
cell granuloma with fungal hyphae within the giant cells.
A detailed otolaryngological and ophthalmological exam-
ination was done for all the patients. The patients had no
evidence of HIV, diabetes, or chronic granulomatous disease
on detailed evaluation in the form of ELISA for HIV, blood
sugar for diabetes, and tetrazolium test for granulocyte
function. Patients with a deranged profile on these tests
(immunocompromised state) were excluded from the study.
A fungal smear was taken for all the patients using part of the
tissue and subjecting it to KOH solution. This was followed by
microscopic examination of the tissue for fungal hyphae, and
culture. Radiology in the form of contrast enhanced com-
puted tomography (CECT) was also undertaken, and occa-
sionally magnetic resonance imaging (MRI) in patients with
intracranial extension or vision loss.Table 1 Grouping of the patients and the management protocol
Group 1 Group 2
Clinical profile Non-axial proptosis
and double vision with
no deterioration of
the vision
Non-axial propto
and double vision
mild deterioratio
the vision
Radiological findings Disease medial to
medial rectus
Disease medial t
optic nerve but l
to medial rectus
Treatment given Endoscopic clearance
and oral itraconazole
for 6 months
Endoscopic parti
clearance and o
itraconazole for
months
Treatment for the
recurrence
Oral itraconazole for 6
months
Oral itraconazole
months
Treatment for the
residual disease
Surgical clearance and
oral itraconazole for 3
months
Amphotericin B
period of 6 week
itraconazole for
monthsDiagnosis was made on the basis of clinical findings like
diplopia, diminution of vision, loss of vision, radiological
findings, and endonasal endoscopic biopsy that showed soft
tissue invasion by hyphae. The patients were grouped accord-
ing to their clinical and radiological profiles into four groups,
with the early stages showing limited symptoms and limited
surgical extent of the disease and advanced stages showing
extensive disease radiologically and adverse symptoms. The
patients were grouped as detailed in Table 1 and managed
using the postgraduate institute management protocol
described in Table 2. All these patients were closely followed
up clinically and radiologically while on treatment, and any
of the patients in groups 1 and 2 who showed clinical or
radiological deterioration were started on injectable ampho-
tericin B for further management. All the patients were
monitored after 3, 6, and 9 months of surgery by repeating
fungal serology and CECT. The maximum follow-up period
was 7 years and the minimum was 9 months.
The resultant morbidity in terms of residual disease and
disease recurrence was noted and the data were analyzed.
Residual disease in our study was defined as persistent dis-
ease even after the completion of treatment, whereas recur-
rent disease was defined as occurring in a clinically normal
person who had had radiological clearance of the disease for
at least 6 months after the completion of treatment. CT
details of the four groups are shown in Figure 1.
Results
A total of 74 patients were enrolled into this study. There
were 52 males and 22 females, with a male to female ratio of
2.4:1. They ranged in age from 26 years to 53 years, with a
mean age of 36.5 years. The duration of symptoms varied
from 3 months to 11 months, with a mean duration of 6.3
months. The most common symptom was forward protrusion
of the eyeball (100%) and the most common sign was uni-
lateral proptosis (100%), followed by restricted ocular mus-Group 3 Group 4
sis
with
n of
Non-axial proptosis
and double vision with
deterioration of the
vision
Axial proptosis with altered
sensorium and loss of vision
o
ateral
Disease lateral to the
optic nerve
Intracranial parenchymal
extension with orbital apex
involvement
al
ral
6
External approach for
partial clearance and
amphotericin B for a
period of 6 weeks
External approach for partial
clearance and amphotericin
B for a period of 6 weeks
for 6 Amphotericin B for a
period of 6 weeks and
itraconazole for a
period of 3 months
Amphotericin B for a period
of 6 weeks and itraconazole
for a period of 6 months
for a
s and
3
Itraconazole for 6
months
Itraconazole for a period of 6
months followed by surgical
extirpation and again
itraconazole for 3 months
Table 2 Postgraduate institute management protocol as given, by group
Group 1 Group 2 Group 3 Group 4
Treatment given Endoscopic clearance
and oral itraconazole
for 6 months
Endoscopic partial
clearance and oral
itraconazole for 6
months
External approach for
partial clearance and
amphotericin B for a
period of 6 weeks
External approach for
partial clearance and
amphotericin B for a period
of 6 weeks
Treatment for the
recurrence
Oral itraconazole for 6
months
Oral itraconazole for
6 months
Amphotericin B for a
period of 6 weeks and
itraconazole for a period
of 3 months
Amphotericin B for a period
of 6 weeks and itraconazole
for a period of 6 months
Treatment for the
residual disease
Surgical clearance and
oral itraconazole for 3
months
Amphotericin B for a
period of 6 weeks
and itraconazole for
3 months
Itraconazole for 6 months Itraconazole for a period of
6 months followed by
surgical extirpation and
again itraconazole for 3
months
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cases (51.35%), and eight of the cases (10.8%) had total loss of
vision. Nasal obstruction was seen in 31% of the cases and
nasal mass in 46%.
The fungal smear was positive in 58 patients (78.4%) using
KOH solution for the tissue analyzed. All patients had histo-
logically proven invasive aspergillosis with a tissue invasion of
the fungus. Seventeen patients (23.0%) required a repeat
biopsy, as it was negative in the first instance.
There were 28 patients in group 1, 18 males and 10
females. All of them underwent endonasal endoscopic biopsy,
and total removal of the disease was carried out. This was
followed up with oral antifungal agents in the form of
itraconazole at a dose of 10 mg/kg/day in two divided doses
for a period of 6months. Three patients died of progression of
the disease with vascular invasion and parenchymal involve-
ment despite starting them on amphotericin B. All the
patients were monitored for the development of any adverse
effects. Post-treatment radiology revealed no residual dis-
ease or recurrence of the lesion.
Therewere22patients in group2, 16males and six females.
In these patients partial removal of the disease was under-
takenbyendonasal endoscopic approach. Thiswas followedup
with oral antifungal drugs in the form of itraconazole at a dose
of 10 mg/kg/day in two divided doses for a period of 6months.
All patients were monitored for the development of any
adverse effects. Four patients died in this group of progression
of the disease with vascular invasion despite administration of
amphotericinB. Post-treatment radiology revealedno residual
disease or recurrence of the lesion in 14 patients, and four
patients showed a residual lesion but were asymptomatic for
the disease. These four patients showed the symptoms again
after a period of 1 year and were subjected to intravenous
amphotericin B at a dose of 1 mg/kg/day for a period of 6
weeks, followed by oral itraconazole for 3 months; post-
treatment radiology was negative. Two of the patients again
developed recurrence after 3 years and required a course of
itraconazole for 6months. The lesion disappeared in one of the
patients. One case with recurrence succumbed to the lesion.
There were 16 patients in group 3, 12 males and four
females. All of them underwent biopsy by external approach,
and partial removal of the disease was carried out. This was
followed up with intravenous amphotericin B at a dose of
1 mg/kg/day for a period of 6 weeks. Six patients in the groupdied of progression of the disease. Post-treatment radiology
revealed no residual disease or recurrence of the lesion in
four patients, and six patients showed a residual lesion.
These patients were then subjected to oral antifungal agents
in the form of itraconazole at a dose of 10 mg/kg/day in two
divided doses for a period of 6 months; post-treatment
radiology was negative in four patients and in two patients
orbital exenteration was done to clear the disease. Four
patients developed recurrence after a period of 1 year and
were subjected to a further course of intravenous amphoter-
icin B, followed by itraconazole for 3 months, and one of
them required exenteration of the orbit. Three patients who
required exenteration of the orbit succumbed to the disease.
There were eight patients in group 4, six males and two
females. All of them underwent biopsy by external approach,
and partial removal of the disease was carried out. This was
followed up with intravenous amphotericin B at a dose of
1 mg/kg/day for a period of 6 weeks. These patients were
monitored for the development of any adverse effects. Three
patients died of progression of the disease. Post-treatment
radiology revealed no residual disease or recurrence of the
lesion in one of the patients, and four patients showed a
residual lesion. These patients were then subjected to oral
itraconazole for 6 months. Post-treatment radiology was
positive again and these patients required craniofacial resec-
tion and orbital exenteration for complete clearance of the
disease. All these patients succumbed to the disease.
Table 2 shows the management given by group to the
patients. Six patients (8.1%) developed hepatitis while on
itraconazole and were changed to intravenous amphotericin
B, and 12 patients (16.2%) developed nephrotoxicity while on
amphotericin B and were switched over to the liposomal
variant of the drug, which these patients tolerated well.
Overall, residual disease was seen in 14 patients (18.9%) and
recurrence was seen in six patients (8.1%). Twenty-four
patients (32.4%) died of the disease in our series, as detailed
in Table 3. Residual disease and recurrent disease were seen
more often in the advanced cases.
Discussion
Fungal infestations of the sinuses can either be non-invasive
or invasive. Non-invasive infections are either allergic sinu-
sitis or sino-nasal fungal ball, wherein bony erosionmay occur
Figure 1 (a) Contrast enhanced computed tomography (CT) scan of the paranasal sinuses and orbit with axial section showing a soft
tissue density in the ethmoids eroding the lamina papyracea extending into the orbit just medial to the medial rectus on the right side,
classified as group 1. (b) Contrast enhanced CTscan of the paranasal sinuses and orbit with axial section showing a soft tissue density in
the ethmoids and the sphenoid eroding the lamina papyracea extending into the orbit encasing the medial rectus and going just medial
to the optic nerve on the right side, classified as group 2. (c) Contrast enhanced CT scan of the paranasal sinuses and orbit with axial
section showing a soft tissue density lateral to the optic nerve in the lateral compartment of the orbit with widening of the orbital apex
region on the right side, classified as group 3. (d) Contrast enhanced CTscan of the paranasal sinuses and orbit with the coronal section
showing soft tissue density involving bilateral superior nasal cavity, ethmoids (posterior) with orbital and intracranial intraparenchymal
extension with surrounding brain edema, classified as group 4.
Postgraduate institute management protocol for invasive Aspergillus flavus sinusitis: is it effective? 137due to decalcification, but with no histological evidence of
invasion of tissue or bone. Invasive infections can either be
localized or fulminant. Localized disease often starts in the
sinuses and spreads to adjacent structures like the orbital
cavity or cranial cavity through focal bony erosion or even
through vessel walls, causing double vision, loss of vision, or
stroke and death. The fulminant form is characterized by
multiple organ involvement.1 In our series, all patients had
localized invasive sino-orbital aspergillosis.
Invasive aspergillosis is a well-known entity in immuno-
compromised patients, with the primary risk factors being
neutrophil defects and corticosteroid use.1 Other predispos-
ing factors include HIV infection, diabetes mellitus, use of
prosthetic devices, trauma, hematological malignancies,etc.1 Rarely has invasive Aspergillus infection been described
in immunocompetent patients. In our series we included only
those patients with no immunocompromise after evaluating
them. The fact that India is an endemic country for the fungal
sinusitis may explain the relatively high number of patients in
our series. We, at the Institute, have consistently reported
this entity of orbital extension of aspergillosis in all its
variants since as early as 1999.6—10 The reasons for its
occurrence in the immunocompetent host is unclear and a
genetic basis for this is being looked into.
The diagnosis is established by histopathology showing
tissue invasion of the hyphae, granuloma formation with
multinucleated giant cells, pressure necrosis, and erosion.
Mauriello et al.,11 Austin et al.,12 and Heier et al.13 have
Table 3 Results achieved following the management protocol
Group No. of patients Residual Recurrence Globe preserved Mortality
Group 1 28 - - 25 (89.3%) 3 (10.7%)
Group 2 22 4 (18.2%) 2 (9.1%) 17 (77.3%) 5 (22.7%)
Group 3 16 6 (37.5%) 4 (25%) 7 (43.8%) 9 (56.3%)
Group 4 8 4 (50%) - 1 (12.5%) 7 (87.5%)
Total 74 14 (18.9%) 6 (8.1%) 50 (67.6%) 24 (32.4%)
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are patients where the diagnosis was made at autopsy.3,14,15
If a diagnosis is not made on first biopsy and the suspicion is
high for the fungal pathology, a second biopsy should be
performed. The diagnosis was established after second
biopsy in 17 of our patients. Our institute started distinguish-
ing the variants of sino-nasal aspergillosis as early as 1995,10
but the eosinophilic variant of allergic rhinosinusitis was
observed for the first time at our institute in 2001.
In our series, the organisms were all identified as Asper-
gillus flavus, whereas in Western countries Aspergillus fumi-
gatus is found more often.1 It is distinguishable on culture
where it shows as yellow—green colonies, with biseriate
conidiophores and a radiate conidial mass arrangement typi-
cal for A. flavus. A. fumigatus normally shows as blue—green
colonies, with uniseriate conidiophores and a columnar
arrangement. Only if the titers were 1:64 was the fungal
serology considered as positive at our institute. The typical
radiological findings are: hyperdense soft tissue on non-con-
trast CTwithin one or more of the paranasal sinuses, may be
mass-like and mimic a malignancy with variable T1 and T2 WI
signal intensity, frequently hypointense on T1 WI and very
hypointense T2 WI, and erosion and possibly expansion of the
involved sinus and invasion of adjacent structures such as the
orbit, anterior cranial fossa, and maxillofacial soft tissues.
The findings were as reported in the literature in our series.
The disease spreads to adjacent structures such as the
orbital cavity or cranial cavity through focal bony erosion or
even through vessel walls, causing compromise of function in
the form of double vision or loss of vision, as was seen in our
patients, in accord with the literature. Most often the sinuses
affected were the ethmoids (anterior followed by posterior),
maxillary sinus, and then the sphenoid sinus where intracra-
nial extension was seen more frequently.
The prognosis of invasive sino-orbital aspergillosis is sig-
nificantly worse than the non-invasive forms of sinus asper-
gillosis,16,17 likely because of penetration of bone and blood
vessel walls, which means that it cannot often be eradicated
by surgery given the anatomic location, and also drug pene-
tration to these areas may be worse. So far the literature
mentions a survival rate of around 30%.18 By following our
above-mentioned protocol for the management of this con-
dition, we achieved a significantly higher survival rate of 67%.
There is no uniformly accepted treatment protocol for this
clinical entity. Management usually begins with surgical deb-
ridement followed by a systemic antifungal drug in the form
of intravenous amphotericin B. The role of radical excision or
orbital exenteration lies in the fact that it reduces the
disease burdenmaking themedical treatment more effective
and gives a better outcome than medical therapy alone.
Hyperbaric oxygen therapy also helps to reduce the diseaseburden. Oxygen in sufficient concentrations is fungicidal and
decreases acidosis thereby increasing tissue survival.19 There
are very few reports in the English literature of the manage-
ment of this entity by itraconazole alone. Massry et al.20 and
Streppel et al.21 have successfully used itraconazole in
patients with sino-orbital aspergillosis. Combinations of itra-
conazole and amphotericin have been used, but there is in
vitro evidence of antagonism.5,21 A few recommend giving
the maximum daily dose of the chosen medication and after
the disease is controlled, prolonged administration of oral
itraconazole to ensure eradication.22—24 This should continue
well past any remaining signs of disease. The results achieved
after such a protocol have resulted in a 30% survival rate.
Data from various sources suggest that response rates of the
different drugs are only 40% to 60%. There is evidence of
resistance to itraconazole as well.25
Our management protocol was based on the extent of the
disease. In limited disease, surgical debridement followed
by oral itraconazole resulted in excellent outcomes, and
amphotericin B with its associated morbidity could be
avoided. In more extensive disease, radical surgical debride-
ment and amphotericin B followed by itraconazole resulted
in a better final outcome. Our choice of antifungal agents
does not reflect present antifungal treatment guidelines.
By following our above-mentioned protocol, we were
able to achieve a survival rate of 67%. This was optimum
management; this was not a single regimen for all patients
regardless of clinical and radiological profile, but appropri-
ate management on the basis of clinical and radiological
extent of the disease.
Conclusions
Using our optimum management protocol, we were able to
reduce themortality of invasive orbital aspergillosis from 80%
as mentioned in the English literature to 32.4% in our study,
with a follow-up of 9 months to 7 years, hence highlighting
the beneficial outcome of the protocol. This may prove to be
a useful management modality for patients with invasive
orbital aspergillosis.
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